Immunity checkpoint blockade with monoclonal antibodies targeting the B7-CD28 superfamily (CTLA-4, PD-1, and PD-L1) produces a durable anti-tumor immune response, and this strategy has been applied in many tumors and translated into clinical benefits [35]. This evidence concerns the gene CD274 and neoplasm.